Bank of America
NGNE icon

Bank of America’s Neurogene NGNE Stock Holding History

Bank of America’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,100
Closed -$231K – 8459
2024
Q4 		$231K Buy
+10,100
New +$376K ﹤0.01% 6046

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Bank of America's NGNE Position: Q1 2026 in Review

Bank of America reduced its Neurogene (NGNE) stake by 74% in Q1 2026, selling an estimated $598K and leaving 10,864 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #5321.

Bank of America first reported a position in NGNE in Q4 2015 and has held it in 36 quarters since. The position peaked at $1.7M in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Bank of America held 10,864 shares of Neurogene worth $219K as of Q1 2026.
  • Bank of America sold 30,895 Neurogene shares in Q1 2026, an estimated $598K.
  • Neurogene made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5321 holding.
  • Bank of America first reported a position in Neurogene in Q4 2015 and has held it in 36 quarters since.
  • Bank of America's Neurogene position peaked at $1.7M in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.